Leiomyosarcoma clinical trials
The registry lists 148 studies for Leiomyosarcoma across more than 10 countries. 34 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-25.
Status
- Completed
- 66
- Recruiting
- 31
- Terminated
- 20
- Active, not recruiting
- 12
- Status unknown
- 9
- Withdrawn
- 6
Phase
- Phase 2
- 88
- Phase 1
- 34
- Phase 3
- 13
- Early Phase 1
- 1
Where
- United States
- 96
- France
- 18
- Canada
- 14
- Spain
- 13
- Italy
- 11
- Australia
- 11
Who runs them
National Cancer Institute (NCI) (21) · Memorial Sloan Kettering Cancer Center (8) · Gynecologic Oncology Group (6) · UNICANCER (3) · M.D. Anderson Cancer Center (3) · Eli Lilly and Company (3) · Massachusetts General Hospital (2) · University of Michigan Rogel Cancer Center (2)
Studies
Recruiting first, then most recently updated. Showing 50 of 148 — search for more.
- Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal SarcomaRecruitingNCT04031677Phase 315 countries
- Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced SarcomaRecruitingNCT05711615Phase 11 country
- A Study of Ivonescimab in People With LeiomyosarcomaRecruitingNCT07516925Phase 21 country
- STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected SarcomasRecruitingNCT06975293Phase 1/21 country
- NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)RecruitingNCT06239272Phase 1/21 country
- A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic TherapyRecruitingNCT07633756Phase 11 country
- Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid TumorsRecruitingNCT07628634Early Phase 11 country
- AOH1996 for the Treatment of Refractory Solid TumorsRecruitingNCT05227326Phase 11 country
- Localized Leiomyosarcoma Biomarker ProtocolRecruitingNCT049250891 country
- Metastatic Leiomyosarcoma Biomarker ProtocolRecruitingNCT056533882 countries
- XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue SarcomaRecruitingNCT06571734Phase 21 country
- Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue SarcomaRecruitingNCT06498648Phase 1/21 country
- A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid TumorsRecruitingNCT06789172Phase 13 countries
- Agnostic Therapy in Rare Solid TumorsRecruitingNCT06638931Phase 21 country
- Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)RecruitingNCT03016819Phase 35 countries
- Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma PatientsRecruitingNCT074329321 country
- Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone SarcomasRecruitingNCT04055220Not applicable1 country
- Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic LeiomyosarcomaRecruitingNCT07125183Phase 21 country
- Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue SarcomaRecruitingNCT07169344Phase 21 country
- Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.RecruitingNCT07173972Phase 21 country
- IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)RecruitingNCT06849986Phase 21 country
- Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced LeiomyosarcomaRecruitingNCT06528769Phase 21 country
- MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue SarcomaRecruitingNCT06277154Phase 21 country
- Beliefs, Attitudes, and Response to Genetic Testing in SarcomaPatientsRecruitingNCT068757001 country
- Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at SanfordRecruitingNCT017931682 countries
- Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the TumourRecruitingNCT06524583Phase 21 country
- Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue SarcomaRecruitingNCT04535271Phase 21 country
- The Role of Pre-Surgical Tru - Cut Biopsy in the Management of Atypical Myometrial LesionsNot yet recruitingNCT065210601 country
- Study on the Quality of Life and Pathological State in Patients Who Underwent Radical CystectomyRecruitingNCT061701771 country
- A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer AgentsRecruitingNCT05094804Phase 1/21 country
- Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA)RecruitingNCT03420014Phase 21 country
- Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma PatientsRecruitingNCT02275286Phase 1/23 countries
- Exploring Clinical Trial Experiences of People With LeiomyosarcomaNot yet recruitingNCT05548179
- Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone SarcomasNot yet recruitingNCT05515068
- A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or DeletionsActive, not recruitingNCT06308419Phase 11 country
- Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by SurgeryActive, not recruitingNCT02923778Phase 22 countries
- Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene AmplificationsTerminatedNCT05827614Phase 11 country
- Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid TumorsActive, not recruitingNCT03851614Phase 21 country
- A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated DiseasesActive, not recruitingNCT04554914Phase 27 countries
- A Study of Rucaparib and Nivolumab in People With LeiomyosarcomaActive, not recruitingNCT04624178Phase 21 country
- Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)TerminatedNCT05712694Phase 33 countries
- Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)Active, not recruitingNCT06088290Phase 312 countries
- Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by SurgeryCompletedNCT02180867Phase 2/33 countries
- APX005M and Doxorubicin in Advanced SarcomaCompletedNCT03719430Phase 21 country
- Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)Active, not recruitingNCT03114527Phase 21 country
- Targeting ATR in Soft-tissue SarcomasCompletedNCT04807816Phase 21 country
- Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue SarcomaActive, not recruitingNCT04200443Phase 21 country
- Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue SarcomaActive, not recruitingNCT04420975Phase 11 country
- Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II TrialCompletedNCT02406781Phase 21 country
- Lenvatinib and Eribulin in Advanced Soft Tissue SarcomaCompletedNCT03526679Phase 1/21 country